Consequences of cystic fibrosis transmembrane regulator mutations on inflammatory cells

dc.creatorGrumelli, Sandra
dc.creatorIslan, Germán Abel
dc.creatorCastro, Guillermo Raúl
dc.date2016-08
dc.date2020-07-13T17:45:48Z
dc.date.accessioned2023-07-14T19:51:37Z
dc.date.available2023-07-14T19:51:37Z
dc.identifierhttp://sedici.unlp.edu.ar/handle/10915/100520
dc.identifierhttps://ri.conicet.gov.ar/11336/49503
dc.identifierhttp://oatext.com/Consequences-of-cystic-fibrosis-transmembrane-regulator-mutations-on-inflammatory-cells.php
dc.identifierissn:2398-3108
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7436967
dc.descriptionRecent studies in cystic fibrosis (CF) transmembrane regulator (CFTR) mutations and function have shed light on its involvement in disease progression. The extent of cell and tissue distribution of CFTR facilitates systemic dysfunction of ion transport in patients carrying a mutation in CFTR, however, its incidences as cofounding risk factor to develop other diseases is not well studied. In this review we differentiate the dysfunctions driven by CFTR mutations in cell of the immune system and their role in CF progression and examine the types of medical treatments available to patients up to date.
dc.descriptionCentro de Investigación y Desarrollo en Fermentaciones Industriales
dc.formatapplication/pdf
dc.format39-51
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightsCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.subjectCiencias Médicas
dc.subjectCystic fibrosis
dc.subjectCFTR-deficiency
dc.subjectCF-immune response
dc.subjectAntibiotic therapies
dc.subjectMicrobioma maintenance
dc.subjectGene therapy
dc.titleConsequences of cystic fibrosis transmembrane regulator mutations on inflammatory cells
dc.typeArticulo
dc.typeRevision


Este ítem pertenece a la siguiente institución